$DMAC
DiaMedica Therapeutics Inc.

2021 Q3 Form 10-Q Financial Statement

#000143774921019480 Filed on August 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.084M $1.209M $1.080M
YoY Change -4.91% 11.94% 24.14%
% of Gross Profit
Research & Development $2.332M $2.156M $1.600M
YoY Change 8.06% 34.75% -14.62%
% of Gross Profit
Depreciation & Amortization $6.000K $2.000K $0.00
YoY Change -40.0%
% of Gross Profit
Operating Expenses $2.332M $2.156M $1.600M
YoY Change 8.06% 34.75% -14.62%
Operating Profit -$3.416M -$3.365M -$2.708M
YoY Change 2.92% 24.26% -1.2%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$27.00K $98.00K $243.0K
YoY Change -121.09% -59.67% -186.79%
Pretax Income -$3.443M -$3.267M -$2.465M
YoY Change 7.9% 32.54% 0.16%
Income Tax $7.000K $7.000K $9.000K
% Of Pretax Income
Net Earnings -$3.450M -$3.274M -$2.474M
YoY Change 8.05% 32.34% 0.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.17
Diluted Earnings Per Share -$181.2K -$174.3K -$174.7K
COMMON SHARES
Basic Shares Outstanding 18.79M 18.79M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.12M $21.33M $11.76M
YoY Change 57.27% 81.44% 7.12%
Cash & Equivalents $16.22M $2.228M $4.955M
Short-Term Investments $31.90M $19.10M $6.800M
Other Short-Term Assets $336.0K $318.0K $290.0K
YoY Change 124.0% 9.66% 45.0%
Inventory
Prepaid Expenses
Receivables $104.0K $16.00K $319.0K
Other Receivables $320.0K
Total Short-Term Assets $48.54M $21.63M $12.40M
YoY Change 56.04% 74.44% 1.0%
LONG-TERM ASSETS
Property, Plant & Equipment $70.00K $73.00K $55.00K
YoY Change 40.0% 32.73% -24.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $127.0K $145.0K $182.0K
YoY Change -22.56% -20.33% -65.07%
TOTAL ASSETS
Total Short-Term Assets $48.54M $21.63M $12.40M
Total Long-Term Assets $127.0K $145.0K $182.0K
Total Assets $48.66M $21.77M $12.58M
YoY Change 55.63% 73.07% -1.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $699.0K $239.0K $552.0K
YoY Change -2.92% -56.7% 110.69%
Accrued Expenses $861.0K $1.132M $609.0K
YoY Change 30.85% 85.88% -3.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000K $5.000K $10.00K
YoY Change -60.0% -50.0% 0.0%
Total Short-Term Liabilities $1.624M $1.440M $1.217M
YoY Change 12.54% 18.32% 28.51%
LONG-TERM LIABILITIES
Long-Term Debt $4.000K $5.000K $10.00K
YoY Change -60.0% -50.0% -50.0%
Other Long-Term Liabilities $0.00 $11.00K $80.00K
YoY Change -100.0% -86.25% -38.46%
Total Long-Term Liabilities $4.000K $16.00K $92.00K
YoY Change -94.2% -82.61% -37.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.624M $1.440M $1.217M
Total Long-Term Liabilities $4.000K $16.00K $92.00K
Total Liabilities $1.628M $1.456M $1.309M
YoY Change 7.67% 11.23% 19.54%
SHAREHOLDERS EQUITY
Retained Earnings -$79.30M -$75.80M -$61.52M
YoY Change 22.55% 23.22% 19.01%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.00M $20.32M $11.27M
YoY Change
Total Liabilities & Shareholders Equity $48.66M $21.77M $12.58M
YoY Change 55.63% 73.07% -1.69%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$3.450M -$3.274M -$2.474M
YoY Change 8.05% 32.34% 0.2%
Depreciation, Depletion And Amortization $6.000K $2.000K $0.00
YoY Change -40.0%
Cash From Operating Activities -$3.046M -$2.092M -$840.0K
YoY Change 29.62% 149.05% -70.83%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K -$3.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$12.83M $993.0K $2.500M
YoY Change -8.39% -60.28% -16.94%
Cash From Investing Activities -$12.83M $990.0K $2.500M
YoY Change -8.37% -60.4% -16.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M $23.00M
YoY Change 30.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.87M 1.000K 0.000
YoY Change 41.01% -100.0%
NET CHANGE
Cash From Operating Activities -3.046M -2.092M -840.0K
Cash From Investing Activities -12.83M 990.0K 2.500M
Cash From Financing Activities 29.87M 1.000K 0.000
Net Change In Cash 13.99M -1.101M 1.660M
YoY Change 189.67% -166.33% 730.0%
FREE CASH FLOW
Cash From Operating Activities -$3.046M -$2.092M -$840.0K
Capital Expenditures -$2.000K -$3.000K $0.00
Free Cash Flow -$3.044M -$2.089M -$840.0K
YoY Change 29.53% 148.69% -70.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Income Loss
OperatingIncomeLoss
-5112000 USD
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18786157
CY2021Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18786157
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18786157
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18746157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18746157
dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
0
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2228000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7409000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Entity Registrant Name
EntityRegistrantName
DiaMedica Therapeutics Inc.
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19067000 USD
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20098000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
318000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
74000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
21629000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27921000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
145000 USD
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
174000 USD
CY2021Q2 us-gaap Assets
Assets
21774000 USD
CY2020Q4 us-gaap Assets
Assets
28095000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
239000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1099000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1132000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
864000 USD
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
64000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1440000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000 USD
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
16000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96126000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94925000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75805000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68909000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20318000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21774000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28095000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2156000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1600000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4562000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2949000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1209000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1108000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2422000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2163000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3365000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2708000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6984000 USD
CY2021Q2 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
-0 USD
CY2020Q2 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
65000 USD
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
-0 USD
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
180000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
178000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
98000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
243000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
102000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
231000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3267000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2465000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6882000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4881000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6896000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4899000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3274000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2487000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6895000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4872000 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18786157
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14139074
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18776461
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13623400
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
511000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3622000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
23145000 USD
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
446000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20318000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000 USD
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
393000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2425000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
13323000 USD
CY2020Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
436000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11272000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6896000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4899000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
957000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
829000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-38000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
23000 USD
dmac Noncash Lease Expense
NoncashLeaseExpense
28000 USD
dmac Noncash Lease Expense
NoncashLeaseExpense
26000 USD
us-gaap Depreciation
Depreciation
12000 USD
us-gaap Depreciation
Depreciation
11000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-324000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-504000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
244000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
146000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-860000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
370000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
239000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-494000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6402000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3822000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
25244000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8799000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
26235000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
980000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2801000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7682000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
241000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7695000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5181000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1072000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2228000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4955000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75800000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6900000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6400000 USD
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
2200000 USD
CY2021Q2 us-gaap Marketable Securities
MarketableSecurities
19100000 USD
CY2021Q2 dmac Working Capital
WorkingCapital
20200000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20300000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68900000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75800000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of credit risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <em style="font: inherit;">one</em> financial institution. These balances generally exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q2 us-gaap Other Receivables
OtherReceivables
16000 USD
CY2021Q2 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
0 USD
CY2020Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000 USD
CY2021Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2000 USD
CY2020Q4 us-gaap Other Receivables
OtherReceivables
49000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
127000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
57000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021Q2 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
638000 USD
CY2020Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
13000 USD
CY2021Q2 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
296000 USD
CY2020Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
360000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
191000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
483000 USD
CY2021Q2 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 USD
CY2020Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
8000 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1132000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
864000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
75000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
34000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
28000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
33000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
79000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
132000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000 USD
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7200
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000 USD
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2753260
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6896000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4899000 USD
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18786157
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14139074
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18776461
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13623400
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
436000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
957000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
829000 USD
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1421092
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2021Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.63
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1183281
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y10M24D

Files In Submission

Name View Source Status
0001437749-21-019480-index-headers.html Edgar Link pending
0001437749-21-019480-index.html Edgar Link pending
0001437749-21-019480.txt Edgar Link pending
0001437749-21-019480-xbrl.zip Edgar Link pending
dm01.jpg Edgar Link pending
dmac-20210630.xsd Edgar Link pending
dmac-20210630_cal.xml Edgar Link unprocessable
dmac-20210630_def.xml Edgar Link unprocessable
dmac-20210630_lab.xml Edgar Link unprocessable
dmac-20210630_pre.xml Edgar Link unprocessable
dmtp20210630_10q.htm Edgar Link pending
dmtp20210630_10q_htm.xml Edgar Link completed
ex_272544.htm Edgar Link pending
ex_272545.htm Edgar Link pending
ex_272546.htm Edgar Link pending
ex_272547.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending